2025-523239-21-00招募中3 期
Open Label Extension (OLE), multiple dose study to evaluate pharmacokinetics, safety, tolerability and efficacy of filgotinib in children and adolescents from 8 years to less than 18 years of age with juvenile idiopathic arthritis (JIA).
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 18
- 试验地点
- 11
- 主要终点
- Frequency and severity of treatment-emergent adverse events (TEAEs), treatment-emergent serious adverse events (SAEs), and TEAEs leading to treatment discontinuation at each visit throughout the duration of the study.
研究概览
简要总结
To determine the long-term safety and tolerability of filgotinib in children and adolescents who completed the parent studies of filgotinib in pJIA and sJIA.
入排标准
- 年龄范围
- 0 years 至 17 years（0-17 Years）
- 接受健康志愿者
- 否
入选标准
- •Subject must have completed treatment with filgotinib in at least one parent study (GLPG0634-CL-131, GLPG0634-CL-329, or GLPG0634-CL-328) and achieved a clinical benefit at the end of the parent protocols.
- •Subject and/or parent/legal guardian must be able and willing to comply with the clinical study protocol requirements and must sign and date the informed consent form and assent (if required per local regulation) as approved by the Independent Ethics Committee/Institutional Review Board, prior to any protocol evaluations.
- •Female or male subject 8 to <18 years of age, on the date of signing the informed consent and assent (per local regulation) form.
- •Female subject of childbearing potential who is sexually active and at risk for pregnancy must agree to use contraception/preventive exposure measures as described in the clinical study protocol.
排除标准
- •Development of any condition during the parent study that would preclude safe continuation.
- •Active infection that is clinically significant, as per Investigator’s judgment.
- •Subject with known hypersensitivity to the components of potential study therapy.
- •Subjects with any condition or circumstances (including abnormalities in laboratory parameters) that, in the opinion of the investigator, may make a subject unlikely or unable to complete the study or comply with study procedures and requirements.
研究组 & 干预措施
GLPG0634, Jyseleca 100 mg film-coated tablets, Jyseleca 200 mg film-coated tablets
Test
干预措施: GLPG0634 (Drug)
结局指标
主要结局
Frequency and severity of treatment-emergent adverse events (TEAEs), treatment-emergent serious adverse events (SAEs), and TEAEs leading to treatment discontinuation at each visit throughout the duration of the study.
Frequency and severity of treatment-emergent adverse events (TEAEs), treatment-emergent serious adverse events (SAEs), and TEAEs leading to treatment discontinuation at each visit throughout the duration of the study.
次要结局
- Percentage of subjects with JIA (ACR) 30 response over time.
- Percentage of subjects with JIA American College of Rheumatology (ACR) 30 response over time.
- Percentage of subjects with JIA ACR inactive disease.
- Percentage of subjects with JIA ACR clinical remission over time.
- Incidence of treatment-emergent uveitis (including severity).
- Duration of response.
研究者
Medical Information
Scientific
Alfasigma S.p.A.
研究点 (11)
Loading locations...
相似试验
招募中
3 期
A Multicenter, Open-label, Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Subjects with Rheumatoid ArthritisRheumatoid arthritis2024-513919-27-00Alfasigma S.p.A.254
招募中
3 期
A study evaluating the effects of filgotinib in children and teenagers with ulcerative colitisUlcerative colitis2024-511458-32-00Alfasigma S.p.A.68
招募中
3 期
Open-Label followed by a Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Infigratinib in Children with HypochondroplasiaHypochondroplasia2024-516822-67-00Qed Therapeutics Inc.32
已完成
3 期
A study to evaluate long-term safety of nintedanib in children and adolescents with interstitial lung disease (InPedILD®-ON)2024-515743-27-00Boehringer Ingelheim International GmbH20
招募中
3 期
A Follow-up Study of Mezagitamab in Adults with Chronic Primary Immune
Thrombocytopenia2025-521692-31-00Takeda Development Center Americas Inc.77